TOP

*Name

Phone

*Email

*Company/Institute

Consultation content

*Verification code

Contact Sales


Sales Image

Contact Sales Assistant


Sales Assistant Image

Contact PM


PM Image
Consult Now
Cutting-edge discovery empowers mRNA vaccine research and development: GentleGen third-generation sequencing service helps to crack the stability code
2025-04-24
Cutting-edge discovery empowers mRNA vaccine research and development: GentleGen third-generation sequencing service helps to crack the stability code
On April 17, 2025, the International Institute of Molecular and Cell Biology in Warsaw, the University of Warsaw, the Medical University of Warsaw and the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences jointly published in Nature, "Re-adenylation by TENT5A enh ances efficacy of SARS-CoV-2 mRNA vaccines" research has brought a new breakthrough to this problem - it is found that TENT5A polymerase can prolong the poly (A) tail of mRNA, stabilize mRNA and enhance immunity. The originality reveals the key mechanism of the efficacy of mRNA vaccine. The stability of mRNA molecules by TENT5A enzyme is a universal mechanism, so it has great potential in medicine.
View More
GentleGen Among Biologics empowers siRNA drug discovery and scientific research and development!
2024-11-04
GentleGen Among Biologics empowers siRNA drug discovery and scientific research and development!
RNAi is an intracellular post-transcriptional gene regulatory mechanism that was discovered in 1998 by Andrew Fire, Craig Mello and others in the Cryptomeria japonica nematode. It was shown that double-stranded RNA can trigger RNAi to catalyze the degradation of complementary mRNA transcripts in Cryptobacterium hidradii nematodes.Andrew Fire, Craig Mello won the Nobel Prize for this in 2006. After 20 years of technology development, the first siRNA drug was approved for marketing and clinical translation in 2018.
View More
Suzhou Junliang Biotechnology Co., Ltd. will accept samples during the Dragon Boat Festival.
2024-10-24
Suzhou Junliang Biotechnology Co., Ltd. will accept samples during the Dragon Boat Festival.
Vacation is approaching, our service program is normal to receive samples, during the vacation period, if you have special needs, please contact the local sales directly. Thank you very much for your trust and support, Junzhong Bio will be committed to oligonucleotide synthesis and modification, gene synthesis, antibody technology research and development and application!
View More
GentleGen innovative mRNA full-length sequence confirmation technology for rapid identification of full mRNA sequences.
2024-10-24
GentleGen innovative mRNA full-length sequence confirmation technology for rapid identification of full mRNA sequences.
Nucleic acid drugs are a new class of biopharmaceuticals that have been extensively researched and developed for the treatment of a wide range of diseases, including cancer, infectious diseases, and genetic disorders. Currently, the main forms of nucleic acid drugs include small nucleic acid drugs (siRNA, ASO, miRNA, tRNA, etc.), linear mRNAs (non-self-replicating and self-replicating mRNAs) and cyclic RNA drugs.
View More
Pre-sales consulting

Pre-sales consulting

A more reliable solution for your needs.
Download

Download

Welcome to our product library.
Sales network

Sales network

Complete sales and service network to ensure product quality.
Event Promotions

Event Promotions

Add to cart now and enjoy this shopping extravaganza!